Managed entry agreements and funding for expensive therapies / Mondher Toumi, Szymon Jaroslawski.
Material type:
TextSeries: Pharmaceuticals, health economics and market accessPublisher: Boca Raton : CRC Press, 2022Edition: First editionDescription: 1 online resourceContent type: - text
- computer
- online resource
- 9781000594676
- 100059467X
- 9781003048565
- 1003048560
- 9781000594638
- 1000594637
- RA410.5
EBSCOhost "EBSCO evaluates our products based on the Web Content Accessibility Guidelines (WCAG) and the related Section 508 and EN 301 549 regulations in the US and EU. Most EBSCO products are substantially conformant with WCAG 2.2 level AA." Source: https://connect.ebsco.com/s/article/EBSCO-VPATs?language=en_US. Last accessed April 22, 2025.
Description based on print version record and CIP data provided by publisher.
Includes bibliographical references and index.
Introduction to managed entry agreements -- From coverage with evidence development to individual performance-based agreements in Italy -- Coverage with evidence development for multiple sclerosis drugs in the UK -- a "costly failure"? -- Novel funding models for expensive therapies -- Definition and classification of MEAs -- Country comparison of the implementation of managed entry agreements.
"Managed Entry Agreements and Funding for Expensive Therapies examines the concept of MEA, detailing how depreciation of some specific therapies through intangible amortization is unavoidable"-- Provided by publisher.
There are no comments on this title.
